Abstract: The present disclosure relates to the technical field of anti-aging preparations for skin, and especially relates to an anti-aging preparation for skin and an application thereof. Components of the anti-aging preparation for skin includes a 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]alkyne]-benzoic acid and/or a salt thereof. In the present disclosure, the anti-aging effect of the 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]alkyne]-benzoic acid and the salt thereof (such as sodium 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]alkyne]-benzoate) on skin has been discovered, and the 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]alkyne]-benzoic acid and the salt thereof can be applied in preparing the anti-aging preparation for skin that has good anti-aging effect on skin.

Abstract: Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one reverse transcriptase inhibitor (RTI).

Abstract: Multi-functional biological compositions are provided for reducing hydric stress and promoting growth in cultivated plants, for use as an inoculant, as a soil conditioner, as a biostimulant, for phosphorus solubilization and for bioremediation in agricultural areas. In particular, compositions containing mixtures of additives and excipients are provided having at least 2 (two) or more species of Bacillus or two or more strains of a single species, or the mutants thereof, concomitantly with additives and excipients, in biological compositions with properties for reducing hydric stress and promoting growth in cultivated plants, for use as an inoculant, as a biological soil conditioner, as a biostimulant, for phosphorus stabilization and for bioremediation in agricultural areas, added to the coating/encrustation used in industrial or non-industrial seed treatment, applied in furrows, using a guided boom or by other application means.

Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseases a sole agent or in combination with other active ingredients.

Abstract: The present disclosure relates generally to lipids, lipid nanoparticle formulations, and methods of using the same for delivering nucleic acids, such as mRNA.

Abstract: A compound represented by formula (I) or its N-oxide, having a controlling effect on a harmful arthropod, Q is a group Q1 or Q2; Z is an oxygen atom; A2, A3, and A6 each a nitrogen atom; A4 is CR1a; A5 is a nitrogen atom; A7 is NR6g; G1 to G4 each is a nitrogen atom; R1a is a C1-C6 chain hydrocarbon group substituted with a cyano group and/or a halogen atom; R2 is a C1-C6 alkyl group optionally substituted with one or more halogen atoms; n is 0, 1, or 2. A composition and method for controlling a harmful arthropod by applying the compound or its N-oxide are also presented.

Abstract: The present disclosure relates to solid state forms of baloxavir marboxil, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: A method of cleaning and disinfecting a surface comprises producing a diluted cleaning disinfectant solution from a concentrated cleaning disinfectant solution, and contacting the surface with the diluted solution. A concentrated cleaning disinfectant solution is stable at freezing temperatures and comprises antimicrobial acid, surface cleaning acid, solubilizing agent, hydrotrope, and surfactant. The antimicrobial acid comprises a synergistic combination of (i) salicylic acid, derivative of salicylic acid, or a combination thereof, and (ii) gluconic acid, derivative of salicylic acid, or a combination thereof. The surface cleaning acid comprises at least one acid selected from mineral acid, methane sulfonic acid, formic acid, or sulfonic acid having an alkyl group with no greater than three carbon atoms. The surfactant selected from anionic surfactant, non-ionic surfactant, or a mixture thereof.

Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.

Abstract: The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to modulate autophagy and lipophagy. HMB is also administered to treat, prevent, inhibit, slow or reduce autophagy-mediated conditions or diseases.

Abstract: The disclosure relates generally to gamma polyglutamated Antifolate, formulations containing liposomes filled with gamma polyglutamated Antifolate, methods of making the gamma polyglutamated Antifolate and liposome containing formulations, and methods of using polyglutamated gamma polyglutamated Antifolate and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and an autoimmune disease such as rheumatoid arthritis).

Abstract: The invention relates to a KRAS mutant protein inhibitor shown as formula (I), a composition containing the inhibitor and the use thereof.

Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.

Abstract: Disclosed are methods, compositions, reagents, systems, and kits to prepare and utilize branched multi-functional macromonomers, which contain a ring-opening metathesis polymerizable norbornene group, one or more reactive sites capable of undergoing click chemistry, and a terminal acyl group capable of undergoing a coupling reaction; branched multi-cargo macromonomers; and the corresponding polymers are disclosed herein. Various embodiments show that the macromonomers and polymers disclosed herein display unprecedented control of cargo loading of agents. These materials have the potential to be utilized for the treatment of diseases and conditions such as cancer and hypertension.

Abstract: A nano-sized [4{3,4-bis-[(5-bromo-2-hydroxy-benzylidene)-amino]-phenyl}-phenyl-methanone] Ru(III) complex, its synthesis, and its use as an anticancer, antioxidant, and antimicrobial agent.

Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing hematological malignancies.

Abstract: The disclosure provides for compounds and methods for modulating or inhibiting glutaminyl-peptide cyclotransferase-like protein (QPCTL). In one aspect, described herein are compounds of Formulas (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), and (IIbb), stereoisomer thereof, or salts or solvates thereof. Further provided herein are methods of treating a disease or a condition comprising administering a compound of Formula (I), (Ia), (Ib), (Iaa), (Iab), (Iba), (Ibb), (II), (IIa), (IIb), (IIaa) (IIab), (IIba), or (IIbb), a stereoisomer thereof, or a salt or solvate thereof.

Abstract: Provided herein are materials and methods useful for reducing, preventing, and/or inhibiting germination of C. perfringens spores, including methods for inhibiting C. perfringens germination to reduce necrotizing enteritis (NE, also referred to as necrotic enteritis) in animals. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.

Abstract: The invention relates to method of treating chronic inflammatory diseases in subjects in need thereof by administering calcium lactate as an active agent. The calcium lactate can be provided in a pharmaceutical, food, or nutrient composition.